ValiRx licenses preclinical prostate cancer treatment
This article was originally published in Scrip
ValiRx, a UK cancer therapeutics and diagnostics company, has signed a licence agreement withCancer Research Technology, the technology transfer arm of the charityCancer Research UK, to evaluate a novel compound known as VAL201 that has been found to inhibit prostate cancer growth in vivo. Under the agreement, ValiRx has 12 months to complete the preclinical development of VAL201, including toxicology, before it has to decide whether it will exercise its option to acquire exclusive worldwide rights to the compound as an anticancer agent and progress it to clinical trials. ValiRx says that early studies suggest that its new lead drug candidate could stop growth of tumours unresponsive to current treatments.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.